Skip to content
value.today

Petros Pharmaceuticals, Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2020
Total raised
$6 M
2 rounds on record
Latest round
$2 M
Dec 2021
First round on record
Nov 2021
Today
Went public
See the company page

Petros Pharmaceuticals, Inc. is listed today as Petros Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Petros Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$30 MPrivate placement after listing$10 to $50 million

Petros Pharmaceuticals, Inc.: Private sale, Jul 2023

Investors in this round

15 investors had bought by the notice of Jul 21, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fady Boctor · Executive Officer · President and Chief Commercial Officer
  • Mitchell Arnold · Executive Officer · Vice President of Finance and Principal Accounting Officer
  • Bruce T. Bernstein · Director
  • Gregory T. Bradley · Director
  • John D. Shulman · Director
  • Joshua N. Silverman · Director
  • Wayne R. Walker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Katalyst Securities LLC (CRD 112494) · New York, New YorkSold in CT, FL, NJ, NY

Remarks in the notice

  • On fees: “Issuer issued to placement agent (and its designees) warrants to purchase up to 533,334 shares at an exercise price of $2.25 (subject to price-based adjustment) under Section 4(a)(2)”
  • On the amounts: “Includes aggregate exercise price of warrants of $2.25 (subject to price-based adjustment), that may be received upon exercise of the warrants”

Signed by Fady Boctor, President and Chief Commercial Officer. Source: SEC Form D, newest notice filed Jul 21, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2021$2 MNo. 2$2 to $10 million

Petros Pharmaceuticals, Inc.: Raise no. 2, Dec 2021

Investors in this round

12 investors had bought by the notice of Jan 3, 2022: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $8 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew R. Gesek · Executive Officer · President, Timm Medical
  • Fady Boctor · Executive Officer · President and Chief Commercial Officer
  • Mitchell Arnold · Executive Officer · Vice President of Finance and Principal Accounting Officer
  • Bruce T. Bernstein · Director
  • Gregory T. Bradley · Director
  • John D. Shulman · Director
  • Joshua N. Silverman · Director
  • Wayne R. Walker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “641406 shares of common stock at $3.43/sh, warrants to purchase up to 1639942 shares of common stock at $3.50/sh, & warrants to purchase up to 110000 shares of common stock at $3.50/sh issued to financial advisor in connection w/ offerings closed 12/27/21”

Signed by Mitchell Arnold, Vice President of Finance and Principal Accounting Officer. Source: SEC Form D, newest notice filed Jan 3, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$4 MNo. 1$2 to $10 million

Petros Pharmaceuticals, Inc.: Raise no. 1, Nov 2021

Investors in this round

12 investors had bought by the notice of Dec 3, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $13 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew R. Gesek · Executive Officer · President, Timm Medical
  • Fady Boctor · Executive Officer · President and Chief Commercial Officer
  • Mitchell Arnold · Executive Officer · Vice President of Finance and Principal Accounting Officer
  • Bruce T. Bernstein · Director
  • Gregory T. Bradley · Director
  • John D. Shulman · Director
  • Joshua N. Silverman · Director
  • Wayne R. Walker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “1180000 shares of common stock at $3/sh, warrants to purchase up to 2500000 shares of common stock at $3.50/sh, & warrants to purchase up to 150000 shares of common stock at $3.50/sh issued to financial advisor in connection w/ offerings closed on 12/2/21”

Signed by Mitchell Arnold, Vice President of Finance and Principal Accounting Officer. Source: SEC Form D, newest notice filed Dec 3, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Petros Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2023

That is all the official record says: Petros Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Petros Pharmaceuticals, Inc. are on record.

Investors#

No investor of Petros Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Petros Pharmaceuticals, Inc.
NameRoleNamed in
Fady BoctorPresident and Chief Commercial OfficerJul 2023
Mitchell ArnoldVice President of Finance and Principal Accounting OfficerJul 2023
Andrew R. GesekPresident, Timm MedicalJan 2022
Bruce T. BernsteinDirectorJul 2023
Gregory T. BradleyDirectorJul 2023
John D. ShulmanDirectorJul 2023
Joshua N. SilvermanDirectorJul 2023
Wayne R. WalkerDirectorJul 2023

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.